Methods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary tract Cancer, Urinary Bladder Cancer, Cervical Uterine  by M. A. HayatMethods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary tract Cancer, Urinary Bladder Cancer, Cervical Uterine  by M. A. Hayat

Methods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary…

EditorM. A. Hayat

Hardcover | December 18, 2009

Pricing and Purchase Info

$452.40 online 
$570.95 list price save 20%
Earn 2,262 plum® points

Prices and offers may vary in store

Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

This sixth volume in the series Methods of Cancer Diagnosis, Therapy, and Prognosis discusses Ovarian Cancer, Renal Cancer, Urogenitary Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma and Sarcoma. Both standard and emerging therapies for these cancers, written by expert oncologists/pathologists in this field, are included.This fully illustrated volumeIdentifies biomarkers based on genetic alterations for clear cell ovarian adenocarcinoma.Identifies subgroups of ovarian cancer by using differential gene expression.Includes the application of the power-Doppler imaging for distinguishing benign from malignant complex adrenal masses in ovarian cancer.Emphasizes the advantage of using cytoreduction surgery for diagnosing advanced ovarian cancer.Provides details on the treatment of kidney cancer with radiofrequency ablation, surgery, and chemotherapy.Explains the use of immunohistochemistry for diagnosing adenomatoid tumor of the adrenal gland.Discusses the chemotherapy of testicular cancer and related second primary tumors.Includes the diagnosis of urothelial bladder cancer with urine-based tumor markers.Explains the use of immunohistochemistry and MRI for diagnosing uterine cervical cancer and describes the staging of this cancer using PET alone or PET/CT.Describes the localization of malignant melanoma using FDG-PET/CT.Explains the use of prognostic receptors for nonmelanoma skin cancer.Details the treatment of multiple myeloma using immunotherapy, radiotherapy, and targeted radionuclide therapy.Presents diagnostic immunohistochemistry of synovial and Kaposi's sarcoma.The technological advances presented in this volume are expected to expedite new discoveries and their translation to clinical practice. The field of oncology will benefit the most from these advanced methods, as a combination of therapies and personalized medicine will improve early detection of these different types of cancer.Professor Hayat has summarized the problems associated with the complexities of research publications and has been successful in editing a must-read volume for oncologists, cancer researchers, medical teachers and students of cancer biology.
Title:Methods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary…Format:HardcoverDimensions:528 pagesPublished:December 18, 2009Publisher:Springer NetherlandsLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:9048129176

ISBN - 13:9789048129171

Look for similar items by category:

Reviews

Table of Contents

PART I. OVARIAN CANCERDiagnosis1. IDENTIFICATION OF BIOMARKERS FOR CLEAR CELL OVARIAN ADENOCARCINOMA; Samuel C. Mok, Michael P. Stanley, Hiroshi Tsuda, and Michael J. BirrerINTRODUCTIONGENETIC ALTERATIONS IN CLEAR CELL OVARIAN CANCERCLEAR CELL OVARIAN CANCER HAS DISTINCT TRANSCRIPTION PROFILESDIFFERENTIAL GENE EXPRESSION IN CLEAR CELL ADENOCARCINOMA OF DIFFERENT ORGANSREFERENCES2. OVARIAN CARCINOMA: DIAGNOSTIC IMMUNOHISTOCHEMISTRY OF MUCIN 4 (MUC4); Moorthy P. Ponnusamy, Ajay P. Singh, Subodh M. Lele, and Surinder K. BatraINTRODUCTIONHISTOPATHOLOGY OF OVARIAN CANCERSTAGES AND PROGNOSIS OF OVARIAN CANCERBIOMARKERS AND SCREENING OF OVARIAN CANCERABERRANT MUCIN EXPRESSION IN OVARIAN CANCERMUCIN 4: Structure and BiologyMUCIN 4 in Ovarian CancerMETHODOLOGY FOR MUCIN4 IMMUNOHISTOCHEMISTRYTissue SectioningImmunolabelingAssessment of MUC4 StainingREFERENCES3. DISTINGUISHING BENIGN FROM MALIGNANT COMPLEX ADNEXAL MASSES IN OVARIAN CANCER: TWO- DIMENSIONAL POWER-DOPPLER IMAGING; Juan Luis AlcazarINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONCONCLUSIONREFERENCES 4. SUBGROUPS OF OVARIAN CARCINOMA: IDENTIFICATION USING DIFFERENTIAL GENE EXPRESSION; Kristin L.M. Boylan, Keith M. Skubitz, and Amy P.N. SkubitzINTRODUCTIONOVARIAN CANCER HETEROGENEITYSELECTION OF SAMPLES FOR GENE MICROARRAY ANALYSISCONTAMINATION OF GENE EXPRESSION PROFILES BY OTHER CELLS IN TISSUESNUMBER OF SAMPLES TO ANALYZE FOR GENE PROFILINGIMPORTANCE OF PATHOLOGICAL QUALITY CONTROLCLINICAL CORRELATIONSGENE MICROARRAY PLATFORMSRNA ISOLATION FOR GENERATING GENE EXPRESSION DATAANAYSIS OF GENE MICROARRAY DATANEED FOR SECONDARY VALIDATION OF DATAGOALS FOR GENE MICROARRAY ANAYSISGENE EXPRESSION ANALYSIS USED TO DETERMINE OVARIANCANCER SUBGROUPSGENE EXPRESSION ANALYSIS USED TO COMPARE DIFFERENT STAGES OR GRADES OF OVARIAN CANCERGENE EXPRESSION PROFILES BASED ON METASTASISCORRELATION OF GENE EXPRESSION PROFILES TO CHEMOTHERAPEUTIC RESPONSECORRELATION OF GENE EXPRESSION PROFILES TO SURGICAL DEBULKINGCORRELATION OF GENE EXPRESSION PROFILES TO PATIENTS' SURVIVALREFERENCES5. SERTOLIFORM ENDOMETRIOID CARCINOMA OF THE OVARY: DIAGNOSIS AND PROGNOSIS; Monalisa Sur and Dean DayaINTRODUCTIONDIAGNOSISClinical FeaturesGross Findings Microscopic FindingsDIFFERENTIAL DIAGNOSISIMMUNOHISTOCHEMISTRYCytokeratinsEpithelial Membrane AntigenInhibinCalretininNeural Cell Adhesion MoleculeEstrogen and Progesterone ReceptorsOther MarkersPROGNOSISREFERENCESPrognosis6. ROLE OF MUC16 (CA125) IN THE PATHOGENESIS OF EPITHELIAL OVARIAN CANCER; Jennifer A. Arens Gubbels, Joseph P. Connor, and Manish S. PatankarINTRODUCTIONCA125 and MUC16MUC16 in Epithelial Ovarian CancerMESOTHELIN AND MUC16 BINDING: A MODEL FOR METASTASISMesothelinMesothelin and MUC16 BindingKinetics of Mesothelin-MUC16 BindingMesothelin Binds to N-Linked Oligosaccharides Present on MUC16MUC16 BINDING TO NATURAL KILLER CELLS: IMMUNOSUPPRESSIVE EFFECTSA Phenotypic ShiftNK Cell DifferentiationTumor Cell Layers of ProtectionREFERENCES7. CLEAR CELL CARCINOMA OF THE OVARY: PROGNOSIS USING CYTOREDUCTIVE SURGERY; Masashi Takano, Naoki Sasaki, and Toru SugiyamaINTRODUCTIONCLINICAL CHARACTERISTICSMOLECULAR CHARACTERISTICSCLINICAL OUTCOMEResistance to Platinum-Based ChemotherapyRetroperitoneal InvolvementPrognosis after Cytoreductive SurgeryREFERENCES8. ADVANCED OVARIAN CANCER: PREDICTION OF SURGICAL OUTCOMES USING COMPUTED TOMOGRAPHY; Sean C. Dowdy and William A. ClibyINTRODUCTIONVALUE OF CYTOREDUCTIONAbility of Computed Tomography to Predict Optimal CytoreductionOTHER TECHNIQUES FOR PREDICTING SURGICAL OUTCOMESCONCLUSIONSREFERENCES PART II. RENAL CANCERTreatment9. RENAL CELL CARCINOMA: FOLLOW-UP WITH MAGNETIC RESONANCE IMAGING AFTER PERCUTANEOUS RADIOFREQUENCY ABLATION; Elmar M. Merkle, Rendon C. Nelson, and Jonathan S. Lewin INTRODUCTIONINVOLUTION OF THE RADIOFREQUENCY-INDUCED THERMAL ABLATION ZONEMAGNETIC RESONANCE SIGNAL CHARACTERISTICS OFRADIOFREQUENCY-INDUCED THERMAL ABLATION ZONESRESIDUAL OR RECURRENT TUMORREFERENCES10. METASTATIC KIDNEY CANCER: TREATMENT WITH INFUSIONAL INTERLEUKIN-2 PLUS FAMOTIDINE; Walter D.Y. Quan Jr., and Francine M. Quan INTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES 11. RENAL CELL CARCINOMA: PREOPERATIVE TREATMENT WITH CYTOKINES FOLLOWED BY SURGERY; Tobias Klatte and Malte BöhmINTRODUCTIONCYTOKINES FROM IMMUNODULATIONInterleukin-2 (IL-2)Interferon-alpha (IFN-alpha)METHODOLOGICAL ASPECTS OF PERIOPERATIVE IMMUNOMONITORINGFlow CytometryEnzyme-Linked Immunosorbent Assay (ELISA)PERIOPERATIVE IMMUNOMODULATION WITH INTERLEUKIN-2PERIOPERATIVE IMMUNOMODULATION WITH INTERFERON-ALPHA OTHER AGENTSCONCLUSIONS AND FUTURE DIRECTIONSREFERENCESPrognosis12. METASTATIC RENAL CELL CARCINOMA: USE OF Bcl-2 AND FAS TO PREDICT RESPONSES TO IMMUNOTHERAPY; Yoshihiko Tomita, Ryo Maruyama, Toshiyuki Itoi, and Vladimir BilimINTRODUCTIONAPOPTOTIC MACHINERY AND TUMOR CELLSFAS-DRIVEN APOPTOSIS AND BCL-2 IN RENAL CELL CANCER CELLSBCL-2 OR FAS AND PROGNOSIS OF RENAL CELL CANCER PATIENTSABSENCE OF BCL-2 AND FAS/CD95/APO-1 PREDICTS THE RESPONSE TO IMMUNOTHERAPY IN METASTATIC RENAL CELL CARCINOMAClinical Course of the PatientsExpression of Bcl-2Expression of FasDetection of Cell Proliferation and ApoptosisCONCLUSIONREFERENCES13. WILMS TUMOR: PROGNOSIS USING MICROVESSEL DENSITY; Yasemin OzlukINTRODUCTIONPROGNOSTIC FACTORS IN WILMS TUMORANGIOGENESISQuantification MethodsAngiogenesis and Wilms TumorREFERENCESPART III. UROGENITARY TRACT CANCERAdrenal14. ADENOMATOID TUMOR OF THE ADRENAL GLAND: DIFFERENTIAL DIAGNOSIS USING IMMUNOHISTOCHEMISTRY; Fanny Burel-Vandenbos, Nathalie Cardot-Leccia, Juliette Haudebourg, Danien Ambrosetti, and Jean-Francois MichielsINTRODUCTIONGENERAL FEATURESHISTOLOGY AND DIFFERENTIAL DIAGNOSISIMMUNOPHENOTYPEREFERENCESTesticular15. TESTICULAR CANCER: POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION; Philippe E. Spiess, Nizar M. Tannir, and Louis L. PistersINTRODUCTIONINDICATIONS FOR POSTCHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTIONPREOPERATIVE CONSIDERATIONSTECHNICAL CONSIDERATIONSTREATMENT-RELATED OUTCOMESPOTENTIAL COMPLICATIONSPOSTOPERATIVE FOLLOW-UPCONCLUSIONREFERENCES16. SURVIVORS OF GERM-CELL TESTICULAR CANCER: INCREASED RISK OF SECOND PRIMARY TUMORS; Lorenzo Richiardi and Milena M. MauleINTRODUCTIONMETHODS TO INVESTIGATE SECOND PRIMARY CANCERSCohort StudiesNested Case-Control Studies Methodological Limitations SECOND PRIMARY CANCERS AMONG SURVIVORS OF TESTICULAR CANCER Testicular Cancers Seminomas and NonSeminomas Chemotherapy and Radiotherapy REFERENCESPART IV. URINARY BLADDER CANCERDiagnosis17. UROTHELIAL BLADDER CANCER: SCREENING WITH URINE-BASED TUMOR MARKERS; Robert S. Svatek and Yair LotanRATIONALEPREVIOUS SCREENING PROGRAMSSCREENING IN PEOPLE WITH OCCUPATIONAL EXPOSUREHEMATURIA SCREENINGURINE-BASED TUMOR MARKERSMETHODOLOGICAL ASPECTS OF MARKER EVALUATIONSpecific Urine-based Tumor MarkersBLADDER TUMOR ASSOCIATED ANTIGEN TESTNUCLEAR MATRIX PROTEIN-22UROVYSIONIMMUNOCYT/ucytCOST-EFFECTIVENESSBASIS AND PITFALLS IN UROTHELIAL BLADDER CANCER SCREENINGFUTURE CONSIDERATIONSREFERENCES 18. DETECTION OF OCT-4 IN BLADDER CANCER: FURTHER EVIDENCE IN SUPPORT OF CANCER STEM CELL HYPOTHESIS; Seyed Javad Mowla, Seyed Mehdi Jafarnejad, and Yaser AtlasiINTRODUCTIONMATERIALSMETHODSHuman Clinical SamplesTotal RNA ExtractionSemi-quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR)Agarose Gel ElectrophoresisWestern BlottingQuantification of the Concentration of Extracted ProteinStripping and Reprobing the MembraneImmunohistochemistryStatistical AnalysesRESULTS Expression of OCT-4 in Tumor and Non-Tumor Tissues of Human BladderTissue Distribution and Intracellular Localization of OCT-4 Protein in Bladder Tumors DISCUSSIONREFERENCESPART V. CERVICAL UTERINE CANCERDiagnosis19. UTERINE CERVICAL GLANDULAR LESIONS: DIFFERENTIATION USING IMMUNOHISTOCHEMISTRY OF MUCINS; Allyson C. Baker, William E. Grizzle, and David ChhiengINTRODUCTIONMETHODS AND MATERIALSRESULTSDISCUSSIONREFERENCES20. UTERINE CERVICAL CARCINOMA: PREOPERATIVE MAGNETIC RESONANCE IMAGING STAGING; Hak Jong Lee and Seung Hyup KimINTRODUCTIONNORMAL ANATOMY OF UTERINE CERVIXGENERAL CONSIDERATION OF UTERINE CERVICAL CANCERMAGNETIC RESONANCE IMAGING TECHNIQUE FOR UTERINE CERVICAL CANCER Magnetic Resonance Findings of Uterine Cervical CancerMagnetic Resonance Staging of Uterine Cervical CancerPELVIC COMPUTED TOMOGRAPHY VERSUS MAGNETIC RESONANCEEvaluation of Pelvic Lymph NodesREFERENCESTreatment21. CANCER IMAGING AND INTERCAVITARY BRACHYTHERAPY FOR CERVICAL CANCER; Shingo Kato and Tatsuya OhnoINTRODUCTIONINTERCAVITARY BRACHYTHERAPY FOR CERVICAL CANCERMAGNETIC RESONANCE IMAGING FOR CERVICAL CANCER BRACHYTHERAPYIMAGE-BASED BRACHYTHERAPYREFERENCESPrognosis22. CERVICAL CANCER: METHODS FOR ASSESSING THE QUALITY OF LIFE; Elfriede GreimelINTRODUCTIONTHE CONCEPT OF QUALITY OF LIFESELECTING APPROPRIATE QUALITY OF LIFE MEASUREMENTSPSYCHOMETRIC PROPERTIES OF QUALITY OF LIFE INSTRUMENTTYPES OF QUALITY OF LIFE MEASUREMENTSDEVELOPMENT OF CROSS-CULTURAL VALIDATION OF QUALITY OF LIFE INSTRUMENTSTHE EORTC MODULAR APPROACH TO QUALITY OF LIFE ASSESSMENTDEVELOPMENT OF THE CERVICAL CANCER MODULEREFERENCES23. CERVICAL CANCER: POSITRON EMISSION TOMOGRAPHY AND POSITRON EMISSION. TOMOGRAPHY/COMPUTER TOMOGRAPHY; Lilie L.Lin and Perry W. GrigsbyINTRODUCTIONBACKGROUND AND STAGINGDIRECTING THERAPYPROGNOSISPOSTTHERAPY MONITORINGREFERENCES24. ENDOMETRIAL CANCER: INDOLEAMINE 2, 3-DIOXYGENASE AS A PROGNOSTIC INDICATOR; Kazuhiko Ino, Eiko Yamamoto, Kiyosumi Shibata, Hiroaki Kajiyama, Akihiro Nawa, and Fumitaka KikkawaINTRODUCTIONMATERIALS AND METHODSAntibodiesPatientsImmunohistochemical StainingEvaluation of Indoleamine 2, 3-Dioxygenase ExpressionStatistical AnalysisRESULTSDISCUSSIONREFERENCESPART VI. SKIN CANCER Melanoma25. NEUROFIBROMATOSIS TYPE 1-ASSOCIATED MALIGNANT MELANOMA: MOLECULAR EVIDENCE OF INACTIVATION OF THE NF1 GENE; Albert RübbenINTRODUCTIONMETHODOLOGYDefinition of Cancer GenesIdentification of Genes Implicated in OncogenesisROLE OF NF1 GENE MUTATIONS IN NF1-ASSOCIATED MELANOMAMelanoma Incidence in NF1Biologic Role of Neurofibromin in MelanocytesMutations of the NF1 Gene in Malignant MelanomaInactivation of the NF1 Gene in NF1-Associated Malignant MelanomaCONCLUSIONREFERENCES26. MALIGNANT MELANOMA: LOCALIZATION AND CHARACTERIZATION USING FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY; Oliver Gheysens and Felix MottaghyINTRODUCTION AND CLINICAL BACKGROUNDUSE OF FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN THE MANAGEMENT OF MALIGNANT MELANOMADETECTION OF LOCOREGIONAL LYMPH NODE INVASIONDETECTION OF DISTANT METASTASES PITFALLS AND ADDITIONAL VALUE OF INTEGRATIVE PET/CT IMAGINGROLE OF FDG-PET IN MONITORING RESPONSE TO THERAPYROLE OF FDG-PET IN PATIENT MANAGEMENTALTERNATIVE TRACERS FOR DIAGNOSING MALIGNANT MELANOMA AND MONITORING THERAPY RESPONSECONCLUSIONREFERENCES27. MALIGNANT MELANOMA VERSUS DEEP PENETRATING NEVUS: DIAGNOSTIC AND PROGNOSTIC IMMUNOHISTOCHEMISTRY OF DIPEPTIDYL PEPTIDASE IV (METHODOLOGY); Alexander Roesch, Michael Landthaler, and Thomas VogtINTRODUCTIONDEEP PENETRATING NEVUS AS A MODEL OF PARADOXICAL MELANOCYTIC INVASIONCOMMON MELANOMA MARKERS FAIL TO SEPARATE MELANOCYTICINVASION FROM TRUE MELANOCYTIC MALIGNANCYIMMUNOSTAINING OF DIPEPTIDYL PEPTIDASE IV DISCRIMINATESMETASTATIC MALIGNANT MELANOMA FROM DEEP PENETRATING NEVUS-APPLICATION OF A NEW HISTOMORPHOLOGIC EXPRESSION ALGORITHM (METHODOLOGY)Tissue Sample Collection and ImmunohistochemistryImmunohistochemical EvaluationDISCUSSION AND BIOLOGIC BACKGROUNDREFERENCESNon-melanoma28. NONMELANOMA SKIN CANCER: USE OF EPHA1 RECEPTOR AS A PROGNOSTIC MARKER; Christian HafnerTHE EPH/EPHRIN FAMILYEPH/EPHRIN EXPRESSION IN ADULT HUMAN TISSUESEPH/EPHRIN EXPRESSION IN HUMAN SKINEPHA1 AND NONMELANOMA SKIN CANCERREFERENCESPART VII. LEUKEMIA29. PRETREATED CHRONIC LYMPHOCYTIC LEUKEMIA: USE OF ALEMTUZUMAB; Michael FieglINTRODUCTIONEVOLUTION OF TREATMENTS FOR CLLALEMTUZUMAB AS MONOTHERAPY IN PRETREATED B-CLLData from the Austrian-Czech RegistryRetreatment with AlemtuzumabCytogenetic Stratification of Alemtuzumab UseCOMBINATION THERAPY WITH ALEMTUZUMAB IN PRETREATED CLLCONSOLIDATION AND MAINTENANCE THERAPY WITHALEMTUZUMAB IN PRETREATED CLLCONCLUSIONREFERENCESPART VIII. MULTIPLE MYELOMA30. IMMUNOTHERAPEUTIC STRATEGIES, RADIOTHERAPY, AND TARGETED RADIONUCLIDE THERAPY APPROACHES FOR THE TREATMENT OF MULTIPLE MYELOMA; Malay Chatterjee, Tridib Chakraborty, Ajay Rana, and Basabi RanaINTRODUCTIONTHERAPEUTIC STRATEGIES IN MULTIPLE MYELOMAMonoclonal AntibodiesAnti-IL-6 TherapyStrategies for Targeting IGF-1Immunotoxins and ImmunoconjugatesRadioimmunoconjugatesMyeloma VaccinesGrowth FactorsManipulation of Immune Cells (Cell Therapy)TARGETED RADIOTHERAPYBone Seeking RadiopharmaceuticalsSkeletal Targeted RadiotherapyCONCLUSIONREFERENCESPART IX. SARCOMADiagnosis31. LOW GRADE FIBROMYXOID SARCOMA: DIAGNOSIS BY DETECTING FUS-CREB3L2 FUSION GENE USING REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION; Atsuji Matsuyama, Masanori Hisaoka, and Hiroshi HashimotoINTRODUCTIONDETECTION OF FUS-CREB3L2 FUSION TRANSCRIPTS USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TUMOR TISSUEPrimersRNA ExtractionRT-PCRSequence AnalysisRESULTS AND EVALUATIONREFERENCES 32. SYNOVIAL SARCOMA: ROLE OF TLE1 AS A DIAGNOSTIC IMMUNOHISTOCHEMICAL MARKER; Jefferson Terry and Torsten O. NielsenINTRODUCTIONMATERIALSMETHODSRESULTS AND DISCUSSIONREFERENCES 33. THE IMMUNOHISTOCHEMISTRY OF KAPOSI'S SARCOMA; Liron Pantanowitz, Gabriel Caponetti, and Bruce J. DezubeINTRODUCTIONMATERIALSMETHODSINTERPRETATIONHISTOGENESISPATHOGENESISHHV8 InfectionAngiogenesisChemokinesApoptosisDIAGNOSISTHERAPYCONCLUSIONREFERENCES34. SYNOVIAL SARCOMA: ROLE OF IMMUNOHISTOCHEMISTRY AND MOLECULAR GENETICS IN DIAGNOSIS AND PROGNOSIS; Andrew HorvaiINTRODUCTIONDIAGNOSISHistologyUltrastructureImmunohistochemistryCytogenetics and Molecular GeneticsIn Situ HybridizationPolymerase Chain ReactionPROGNOSTIC MARKERS FOR SYNOVIAL SARCOMAREFERENCESTreatment35. SARCOMA: TREATMENT WITH ECTEINASCIDIN-743; Jérôme Fayette, Philippe Cassier, Laura Brousseau, Armelle Dufresne, Isabelle Ray Coquard, Laurent Alberti, Pierre Méeus, Anne-Valérie Decouvelaere, Marie-Pierre Sunyach, Dominique Ranchère, and Jean-Yves BlayINTRODUCTIONMECHANISMS OF ACTION AND RESISTANCEMETABOLISM AND TOXICITY OF ECTEINASCIDIN-743CLINICAL ACTIVITY OF ECTEINASCIDIN-743 IN PATIENTS WITH SARCOMAECTEINASCIDIN-743 COMBINATION WITH OTHER DRUGSREFERENCES